Cipro is a powerful antibiotic used to treat a variety of bacterial infections. However, the medication is also associated with a number of potentially serious complications, including peripheral neuropathy and tendon injuries.
Cipro (ciprofloxacin) is a fluoroquinolone antibiotic marketed by Bayer AG that has been on the market since 1987. It is currently approved to treat:
The U.S. Food & Drug Administration (FDA) is warning that the risks associated with Cipro, including serious complications affecting the nerves, muscles, tendons and central nervous system, outweigh its benefits for patients with certain uncomplicated infections. According to an alert issued in May 2016, the labels for Cipro and other fluoroquinolone antibiotics will be updated with a new boxed warning. Read More
Cipro has been linked to some very serious complications, prompting the U.S. Food & Drug Administration (FDA) to issue several safety alerts in recent years for this and other fluoroquinolone antibiotics:
Since 2013, hundreds of lawsuits have been filed against the manufacturers of Cipro and other name-brand fluoroquinolones, all of which accuse Bayer and other defendants of failing to adequately warn doctors and patients about the potential for serious nerve damage and peripheral neuropathy. These complaints point out that the link between peripheral neuropathy and the use of these medications was recognized in 2001, when a study published in the Annals of Pharmacotherapy detailed 45 cases of the condition among people treated with the antibiotics. At least 84% of the cases were characterized as “severe,” while more than half persisted for a year or more.
In August 2015, the U.S. Judicial Panel on Multidistrict Litigation (JPML) transferred all federal peripheral neuropathy lawsuits involving fluoroquinolone antibiotics to the U.S. District Court, District of Minnesota. Centralization of the docket will improve judicial efficiency by allowing these cases to undergo coordinated pretrial proceedings. Read More
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.